Latanoprost And Timolol Accord

Timolol maleate and latanoprost, the active ingredients in Latanoprost And Timolol Accord, form a beta‑blocker/prostaglandin‑analog combination presented as sterile ophthalmic eye drops for ocular administration. The formulation is indicated for the reduction of intra‑ocular pressure in adults with open‑angle glaucoma or ocular hypertension, helping to preserve visual function.

GNH USA supplies Latanoprost And Timolol Accord as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under strict quality‑assurance standards.

Latanoprost and timolol eye drops are used to manage conditions that involve elevated intra‑ocular pressure.

Open‑angle glaucoma: lowers intra‑ocular pressure to slow disease progression. Ocular hypertension: reduces elevated eye pressure to prevent conversion to glaucoma. Secondary ocular hypertension: decreases pressure caused by other ocular conditions.

Common Side Effects: - Eye irritation or burning sensation. - Blurred vision shortly after instillation. - Redness of the conjunctiva. - Increased eyelash growth or darkening of the iris.

Serious or Rare Side Effects: - Severe allergic reaction with swelling or rash. - Marked bradycardia or hypotension. - Bronchospasm in susceptible patients. - Persistent eye pain or vision loss. - Corneal ulceration.

Precautions should be observed before prescribing this combination therapy. - Assess cardiac status: avoid in patients with severe bradycardia or heart block. - Monitor respiratory function: caution in asthma or chronic obstructive pulmonary disease. - Check for hypersensitivity: discontinue if allergic reaction occurs. - Avoid concurrent systemic non‑selective beta‑blockers: may increase systemic effects. - Pregnancy and lactation: use only if clearly needed; safety not established. - Store at room temperature: keep in original container, protect from light and moisture.

Potential drug interactions must be reviewed.

Major Interactions (Avoid): - Systemic non‑selective beta‑blockers: may cause additive bradycardia. - Adrenergic agonists (e.g., epinephrine eye drops): may reduce ocular hypotensive effect. - Other prostaglandin analogs: increased risk of ocular inflammation.

Moderate Interactions (Monitor Closely): - Topical anesthetics: may increase corneal toxicity. - Anticholinergic eye drops: may affect pupil size and intra‑ocular pressure. - Systemic antihypertensives: monitor blood pressure for additive lowering effect.